Wockhardt hopes to complete Phase III trials for Zaynich by Q1 of 2025

So far it has supplied the compound to 30 patients for compassionate use with range of life-threatening infections

Related Keywords

Zaynich Zidebactam Cefepime ,Zidebactam Cefepime ,Central Drugs Standard Control Organisation ,Wockhardt Ltd ,Global Pharmaceutical ,New Drug Discovery ,Qualified Infectious Disease Product ,